A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an inborn error of immunity with clinical manifestations including infections, lymphoproliferation, autoimmunity, enteropathy, bronchiectasis, increased risk of lymphoma, and early mortality. Hyperactive PI3Kδ signaling causes APDS...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, V. Koneti, Webster, Sharon, Šedivá, Anna, Plebani, Alessandro, Schuetz, Catharina, Shcherbina, Anna, Conlon, Niall, Coulter, Tanya, Dalm, Virgil A., Trizzino, Antonino, Zharankova, Yulia, Kulm, Elaine, Körholz, Julia, Lougaris, Vassilios, Rodina, Yulia, Radford, Kath, Bradt, Jason, Kucher, Klaus, Relan, Anurag, Holland, Steven M., Lenardo, Michael J., Uzel, Gulbu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Plenary Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163280/
https://www.ncbi.nlm.nih.gov/pubmed/36399712
http://dx.doi.org/10.1182/blood.2022018546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163280/
https://www.ncbi.nlm.nih.gov/pubmed/36399712
http://dx.doi.org/10.1182/blood.2022018546

Ejemplares similares